<unk>  has been approved for use immediately following an elective Cesarean section when a local or spinal anesthesia has been used. Since the uterus cannot contract on its own following incision during a Cesarean section, exogenous administration of oxytocin or an analog is necessary to restore uterine tone and prevent hemorrhage. Safety of<unk>  following vaginal births and emergency Cesarean sections has not been established, though studies have suggested efficacy following vaginal births to that following Cesarean sections. Some studies have shown that a 10-70ug dose following vaginal delivery caused contractions and no adverse side effects.<unk>  has also been shown to increase uterine involution (the return of the uterus to its contracted state after the birth of the baby) in humans, horses and cows. Comparison with other medication In 2018, heat-stable<unk> , a formulation that does not require strict refrigeration, was found to be as good as oxytocin for reduction of postpartum hemorrhage after vaginal delivery. It is hoped that this will make oxytocic hemorrhage control more widely available and less expensive, which will be particularly useful in regions of developing countries where the cold chain (in drug transport and storage) is unreliable because of power outages or equipment problems. Due to<unk> 's considerably longer half-life, its effects are longer lasting than other oxytocin homologs such as oxytocin or barusiban. A single<unk>  dose compared to a placebo or an eight-hour intravenous drip of oxytocin in a randomized blind study, necessitated less additional oxytocin therapy following a Cesarean section. Oxytocin receptor antagonists, such as barusiban or atosiban have the opposite effect of depressing oxytocin receptor activity and can be used to stop premature labor and uterine contractions.
Carbetocin
Betamethasone
Chloroxylenol
Oxytocin 
Oxytocin
Progestogen 
Progestogen
Psilocin